Perimeter Medical Imaging AI to Present at the 13th Annual LD Micro Main Event Investor Conference albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
(2)
TORONTO, ON / ACCESSWIRE / December 11, 2020 / Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(FSE:4PC), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, announced today that Jeremy Sobotta, Perimeter s Chief Executive Officer, will present a corporate overview at the 13th Annual LD Micro Main Event (virtual) investor conference on Monday, December 14, 2020 at 12:40 pm ET.
The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform, and it features a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
KVD900 Phase 2 Clinical Trial Patient Treatment Completed; Data Expected Q1 2021 -
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2020. We have completed the patient treatment phase of our KVD900 Phase 2 trial and are in the process of wrapping up that study. Data from this trial evaluating KVD900 as an oral on-demand treatment for hereditary angioedema is expected in the first quarter of 2021, said Andrew Crockett, Chief Executive Officer of KalVista. The formulation data recently shared for KVD824, our oral prophylactic treatment candidate for HAE, showed concentrations that we believe can lead to efficacy levels competitive with